- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Positron and GE extend buyout deadline
Positron and GE Medical Systems have extended the deadline forPositron to complete its acquisition of GE's PET assets (SCAN7/31/96). The deadline, originally set for the end of last year,has been extended until March 31. Positron, of Houston, TX, saidthe
Positron and GE Medical Systems have extended the deadline forPositron to complete its acquisition of GE's PET assets (SCAN7/31/96). The deadline, originally set for the end of last year,has been extended until March 31. Positron, of Houston, TX, saidthe extension enables it to complete regulatory requirements andto finalize its financing package.
In other Positron news, the company last month announced two PETsystem orders: one to a mobile imaging company that will set upa mobile PET route in the Cleveland area, and another to a customerin the New York City area. Positron now has four PET scanner ordersin its backlog.
Also last month, Positron entered a sales and marketing agreementwith Beijing Aerospace Chang Feng Medical Devices, which willsell Positron PET systems in China. Chang Feng is the largestsupplier of CT and MRI scanners in China, according to Positron.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
